Healthstar Medical Gets NMPA Approval for KC1036 Clinical Study in Juventus sarcoma

Beijing-based Healthstar Medical Development Co., Ltd (SHA: 603590) has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its drug candidate KC1036 in advanced Juventus sarcoma for adolescents aged 12 and above.

KC1036, a tyrosine kinase inhibitor (TKI) that targets AXL, VEGFR2, and FLT3, is currently under investigation in multiple clinical studies for various types of tumors, including those of the digestive system and thymic tumors. The drug has demonstrated significant anti-tumor activity and safety in clinical settings.- Flcube.com

Fineline Info & Tech